Products
ViperaTAb™
Affinity Purified, European Viper Antivenom (Ovine Fab for Injection)
Indication
European common adder (Vipera berus) envenomation
Description
Although not an approved or marketed drug, ViperaTAb™ is available in Europe on a named patient basis. ViperaTAb™, a Polyvalent Immune Fab (Ovine), comprises specific antibody fragments that bind and neutralise Vipera berus venom components, including proteases, lipases and cardiotoxins, facilitating their redistribution away from target tissues and subsequent elimination from the body.
ViperaTAb™ is an antidote for the treatment of snakebites from the European common adder (Vipera berus), offering a treatment for the 750 bites which occur each year in the Europe*. This product is currently available on a named patient basis in Sweden, Finland, Norway, Denmark, Iceland, Estonia, Latvia, Lithuania and Germany under an agreement with Swedish Orphan Biovitrum International AB (www.sobi.com), and in other territories by Flynn Pharma Limited (www.flynnpharma.com).
Contact details for these distributors are:
SOBI: +46 8 697 20 00
Flynn Pharma: +44 1438 727822
(*MicroPharm estimates; based on Reading, CJ (1996) Incidence, pathology and treatment of adder (Vipera berus L) bites in man. Journal of Accident and Emergency Medicine, 13, 346-351)
EchiTAbG™
An antivenom for the treatment of envenomation by Echis ocellatus (carpet viper).
This product was developed in collaboration with the Nigerian Federal Ministry of Health.
Product Pipeline
MicroPharm is developing several products based upon ovine polyclonal antibodies. These include treatments for:
- Clostridium difficile infections
- Colchicine poisoning
- Envenomation by all species of Vipera for veterinary use
